07:55 AM EDT, 05/16/2025 (MT Newswires) -- BioMarin Pharmaceutical ( BMRN ) said Friday that it has agreed to acquire Inozyme Pharma ( INZY ) at $4 per share in cash for a total price of $270 million.

The biotech company said the deal is expected to close in Q3, which is contingent on regulatory approval, completion of a tender offer, and other customary closing conditions.